A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BPI-21668 in Advanced Solid Tumor Patients
Latest Information Update: 27 Apr 2022
At a glance
- Drugs BPI-21668 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Betta Pharmaceuticals Co Ltd
Most Recent Events
- 27 Apr 2022 New trial record